Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo
Investors sentiment increased to 1.31 in 2019 Q3. Its up 0.14, from 1.17 in 2019Q2. It increased, as 37 investors sold Vertex Pharmaceuticals Incorporated shares while 166 reduced holdings. 62 funds opened positions while 204 raised stakes. 234.70 million shares or 0.28% less from 235.36 million shares in 2019Q2 were reported.
Private Advisor Lc reported 0.02% stake. Signaturefd Lc stated it has 1,226 shares or 0.02% of all its holdings. Baystate Wealth Lc has 110 shares. Bridgewater Assoc Ltd Partnership has invested 0.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Evercore Wealth Limited Liability Com has 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1,912 shares. Stephens Incorporated Ar reported 10,660 shares. Cibc World Mkts Corporation holds 0.16% or 101,597 shares. Mufg Americas Holding, a New York-based fund reported 375 shares. Bp Pcl holds 25,600 shares or 0.16% of its portfolio. Smithfield Trust holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 262 shares. Baldwin Brothers Ma invested 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). First Interstate Bankshares owns 684 shares for 0.03% of their portfolio. Next Century Growth Investors Limited Liability Com has invested 0.52% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Optimum Investment has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Clearbridge Invs Limited Com invested 0.74% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 16 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 15 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Vertex Pharmaceuticals has $25400 highest and $203 lowest target. $229.56’s average target is 2.83% above currents $223.25 stock price. Vertex Pharmaceuticals had 30 analyst reports since August 1, 2019 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Thursday, October 31 with “Buy”. On Thursday, August 1 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Monday, October 21, the company rating was maintained by Jefferies. On Thursday, August 1 the stock rating was maintained by Piper Jaffray with “Overweight”. The stock has “Buy” rating by Stifel Nicolaus on Thursday, October 31. The firm has “Buy” rating by Citigroup given on Tuesday, October 22. The rating was maintained by J.P. Morgan on Monday, October 21 with “Buy”. The company was maintained on Thursday, October 24 by Piper Jaffray. The firm has “Buy” rating given on Monday, October 21 by Robert W. Baird. Goldman Sachs maintained it with “Buy” rating and $25400 target in Tuesday, September 3 report. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

21/11/2019 Broker: BidaskScore Rating: Buy Upgrade
20/11/2019 Broker: Bank of America Rating: Buy Old Target: $235.0000 New Target: $245.0000 Maintain
19/11/2019 Broker: Cantor Fitzgerald Rating: Overweight Old Target: $217.0000 New Target: $229.0000 Maintain
12/11/2019 Broker: SunTrust Rating: Buy New Target: $235.0000 Initiates Coverage On
31/10/2019 Broker: Maxim Group Rating: Hold Maintain
31/10/2019 Broker: RBC Capital Markets Rating: Buy New Target: $235 Maintain
31/10/2019 Broker: Piper Jaffray Rating: Overweight Old Target: $230.0000 New Target: $247.0000 Maintain
31/10/2019 Broker: Stifel Nicolaus Rating: Buy Old Target: $211.0000 New Target: $229.0000 Maintain
31/10/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $240.0000 New Target: $250.0000 Maintain
24/10/2019 Broker: Piper Jaffray Rating: Buy New Target: $230 Maintain

The stock increased 0.08% or $0.18 during the last trading session, reaching $223.25. About 987,621 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has declined 4.47% since December 7, 2018 and is downtrending. It has underperformed by 4.47% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $57.41 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 27.09 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “3 Top Stocks to Buy in November – Nasdaq” on November 10, 2019, also Finance.Yahoo.com with their article: “Here’s Why I Think Vertex Pharmaceuticals (NASDAQ:VRTX) Might Deserve Your Attention Today – Yahoo Finance” published on July 04, 2019, Bizjournals.com published: “FDA intervenes for 3rd time in Solid Biosciences’ Duchenne drug tests – Boston Business Journal” on November 12, 2019. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Bizjournals.com and their article: “CRISPR Therapeutics stock jumps on early gene editing data – New York Business Journal” published on November 19, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout – Yahoo Finance” with publication date: November 19, 2019.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link